摘要
目的 :观察哌拉西林 /他唑巴坦钠 (特治星 )在治疗医院内获得性肺部感染中的临床疗效。方法 :80例医院内获得性肺部感染患者随机分为 2组各 4 0例 ,分别给予特治星与头孢他啶静脉滴注 ,并观察临床指标、细菌学情况、临床疗效及安全性。结果 :特治星组与头孢他啶组的有效率分别为 92 5 %、72 5 % ,细菌清除率分别为88%、6 6 7% ;细菌敏感率分别为 80 5 %、75 6 %。特治星组疗效及细菌清除率均明显高于头孢他啶组 (P <0 .0 5 ) ,细菌敏感率比较差异无显著性 (P >0 .0 5 )。不良反应均短暂且较轻 ,未发现对肝肾功能的损害。结论 :特治星是一种广谱、安全的抗生素 ,可有效治疗医院内获得性肺部感染 ,值得临床推广。
Objective: To study the clinical effect of tazocin in the treatment of hospital acquired pneumonia. Methods: 80 cases of hospital acquired pneumonia were randomly divided into tazocin treatment group (40 cases) and ceftazidim treatment group (40 cases). The therapeutic effect and safety were compared between the two groups. Results: The effective rate, bacteria eradication rate and bacteria sensitivity rate were 72.5 %, 66.7 % and 80.5 % respectively in tazocin group, while the counterpart indexes were 80 %, 69.6 % and 75.6 % respectively in ceftazidim group. The effective rate and bacteria eradication rate in tazocin treatment group were higher than in cefazidim treatment group (P<0.05), but there was no significant difference in bacteria sensitivity rate between the two groups (P>0.05). Both two groups had transient and slight side-effects. Conclusion: Tazocin is a safe and effective oral antibiotic for treatment of acute trachea-bronchitis.
出处
《中国康复》
2003年第4期231-232,共2页
Chinese Journal of Rehabilitation
